correction of impaired platelet thromboxane receptor signaling. Am J Physiol Cell Physiol 279: C1760-C1771, 2000.-This study evaluated the mechanism of epinephrine potentiation of platelet secretion induced by thromboxane A 2 (TXA 2 ). Dog platelets that do not secrete in response to TXA 2 alone (TXA 2 Ϫ) were compared with dog platelets that do secrete (TXA 2 ϩ) and with human platelets. TXA 2 Ϫ platelets had impaired TXA 2 receptor (TP receptor)-G protein coupling, indicated by 1) impaired stimulated GTPase activity, 2) elevated basal guanosine 5Ј-O-(3-thiotriphosphate) binding, and 3) elevated G␣ q palmitate turnover that was corrected by preexposure to epinephrine. Kinetic agonist binding studies revealed biphasic dog and human platelet TP receptor association and dissociation. TXA 2 Ϫ and TP receptor-desensitized TXA 2 ϩ dog and human platelets had altered ligand binding parameters compared with untreated TXA 2 ϩ or human platelets. These parameters were reversed, along with impaired secretion, by epinephrine. Basal phosphorylation of TXA 2 Ϫ platelet TP receptors was elevated 60% and was normalized by epinephrine. Epinephrine potentiates platelet secretion stimulated by TXA 2 by reducing basal TP receptor phosphorylation and facilitating TP receptor-G protein coupling in TXA 2 Ϫ platelets and, probably, in normal platelets as well.
activation either by enhancing the binding of agonists to TXA 2 receptors (TP receptors) or by the coupling of TP receptors to phosphoinositide-specific phospholipase C (PLC) (2) . This hypothesis was of interest to us because of our previous observation that dog platelets, which showed little or no response to TXA 2 alone, had impaired signal transduction via G proteins from TP receptors to PLC (18) , but they aggregated and secreted their granular contents if exposed to epinephrine before TXA 2 (6, 18, 21, 22) .
Most dogs, whether random or purpose bred, have blood platelets that form TXA 2 , but they have very impaired secretion and aggregation in response to TXA 2 (5, 6, 18, 21, 22) . These TXA 2 -insensitive (TXA 2 Ϫ) dog platelets also have impaired responses to TXA 2 (18) . However, some mixed breeds, and a few purpose-bred dogs, have TXA 2 -sensitive (TXA 2 ϩ) platelets (6, 18, 21 ) that secrete and aggregate in response to TXA 2 or TXA 2 analogs as do human platelets. Each dog's platelet response to TXA 2 is consistent and genetically determined (20) .
analogs such as U-46619 or I-BOP {[1S-[1␣,2␣(Z),3␤(1E,3S*),4␣]]-7-[3-[3-hydroxy-4-(4-iodophenoxy)-1-butenyl]-7-oxabicyclo (2.2.1)hept-2-yl]-5-heptenoic acid}
TP receptors belong to the family of G protein-coupled receptors (GPCRs) that activate effectors via G proteins (16) . Agonist binding to platelet TP receptors activates G␣ 13 , which results in platelet shape change (24) , and G␣ q , which in turn activates PLC ␤-isoforms (PLC-␤) (3, 19, 17, 34) . Activation of PLC-␤ liberates two important intracellular messengers: D-myo-inositol 1,4,5-trisphosphate (IP 3 ) and diacylglycerol (DG). The subsequent elevation of the cytosolic ionized calcium concentration by IP 3 and activation of protein kinase C by DG lead to platelet secretion. Previous investigation of the mechanism responsible for TXA 2 Ϫ platelets implicated defective signaling from TP receptors via G proteins to PLC-␤ (18) . Subsequent study found no mutation in G␣ q in TXA 2 Ϫ platelets (19) . Therefore, we sought evidence of an alternative mechanism.
An important characteristic of dog TXA 2 Ϫ platelets is the reversibility of their functional defect by epinephrine. Exposure of TXA 2 Ϫ platelets to epinephrine before exposure to TXA 2 or TXA 2 analogs results in aggregation and secretion comparable to that observed in TXA 2 ϩ platelets (6, 18, 21, 22) . Therefore, we studied the effects of epinephrine on several aspects of dog TXA 2 Ϫ platelet TP receptor signal transduction including G q function, PLC-␤ activation, TP receptor kinetic agonist binding, and phosphorylation. Because we observed that human platelets with homologously desensitized TP receptors had their defective activation of PLC-␤ corrected by exposure to epinephrine in a manner similar to that of dog TXA 2 Ϫ platelets, we also studied the mechanism of epinephrine correction of human platelets. These studies indicated that epinephrine corrects the signaling defect of dog TXA 2 Ϫ platelets and desensitized human platelets by facilitating G q -TP receptor coupling. In TXA 2 Ϫ platelets the corrective effect of epinephrine appears to be mediated by dephosphorylation of hyperphosphorylated TP receptors. 
MATERIALS AND METHODS

Materials
Antisera
Antisera N345 and N432 were commercially produced (HRP, Dover, PA) in rabbits by injection of synthetic peptides coupled to keyhole limpet hemocyanin (Pierce conjugation protocol). The dilution of whole antisera used is designated for each experiment. Antiserum N345 recognizes an internal sequence in G␣ q (19) , and N432 recognizes a third TP receptor internal loop sequence (HGQEAAQQRPRDSEV).
Subjects
Dogs with well-characterized TXA 2 Ϫ or TXA 2 ϩ platelets were maintained in an American Association for Accreditation of Laboratory Animal Care-certified animal care facility. Human subjects were normal healthy volunteers who had taken no medication within the previous week. This study was approved by the Animal Studies and Human Studies Subcommittees of the Research Committee of the Minneapolis Veterans Affairs Medical Center.
Platelet Preparation
Platelets were prepared as described previously (18) and were resuspended with HEPES citrate buffer for binding assays. For receptor phosphorylation and IP 3 generation studies, the resuspension buffer was HEPES Tyrode buffer (18) . In [
14 C]5-HT secretion studies, the resuspension buffer was modified Lindon's buffer (18) . Platelet membranes were prepared by the method of Baldassare et al. (1) .
GTPase Activity
Platelet membrane GTPase activity was assayed by standard methods (18) .
Binding of [ 35 S]GTP␥S to Platelet Membranes
Binding experiments were conducted as described by Gachet et al. (11) . Aliquots of platelet membranes, resuspended via sonication, were diluted to ϳ6 mg/ml. The reaction mixture for measuring [ 35 S]GTP␥S binding contained 50 mM Tris ⅐ HCl (pH 7.4), 100 mM NaCl, 5 mM MgCl 2 , 1 mM EDTA,
, buffer or agonist (12 nM I-BOP), and ϳ900 g of membrane protein in a volume of 1,200 l. The reaction was started by the addition of the membrane suspension, and duplicate samples (75 l) were removed immediately and at 2, 4, 6, 10, 30, and 60 min after addition and diluted into 10 ml of wash buffer. The reaction was terminated by rapid filtration through 0.45-m nitrocellulose filters under vacuum, and the filters were washed with 10 ml of buffer. Radioactivity bound to the membrane filters was determined via scintillation counting. Nonspecific binding, determined in the presence of 266 M cold GTP␥S, amounted to ϳ2.5% of the added [ 35 S]GTP␥S and was subtracted from the total bound radioactivity to determine specific activity. The intra-assay variation between duplicates was Ͻ5% of the mean.
[ 3 H]Palmitate Labeling
Palmitate exchange in platelets was determined by the method of Hallak et al. (15) . Platelets (3 ϫ 10 9 ) suspended in 2 ml of acylation buffer (140 mM NaCl, 2.5 mM KCl, 0.1 mM MgCl 2 , 10 mM NaHCO 3 , 0.5 mM NaH 2 PO 4 , 5.5 mM glucose, and 10 mM HEPES, pH 7.4, containing 3.6 mg/ml fatty acid-free BSA, 1 U/ml apyrase, and 0.3 M PGE 1 ). [ 3 H]palmitate (1 mCi) was dried under nitrogen and dissolved in 1 ml of acylation buffer. Both palmitate and cells were incubated at 37°C for 3 min before the reaction was initiated. For stimulated exchange reactions, 30 l (1:200 dilution) of stock I-BOP were added to the palmitate tube (final concentration 12.5 nM I-BOP). The reaction was initiated by combining the cells with the palmitate, and 315-l aliquots were withdrawn at 2, 5, 9, 15, 24, and 60 min, diluted into 3.75 ml of HEPES citrate containing 25 l of 0.1 M EDTA, and centrifuged at 1,700 rpm for 10 min. The supernatant was removed, and 90 l of SDS disruption buffer (50 mM NaPO 4 , pH 8.0, 0.5% SDS, and 2 mM EDTA) were added to the pellet. The cells were vortexed, heated at 90°C for 5 min, and cooled, and 30 l of 4ϫ RIPA (200 mM NaPO 4 , pH 7.2, 4% deoxycholate, 4% Triton, 0.6 M NaCl, 2% SDS, and 8 mM EDTA) plus inhibitors (1% aprotinin, 200 g/ml leupeptin) were added. Each sample (ϳ150 l) was clarified, with 2 l of preimmune sera and 25 l of protein A-Sepharose, for 3 h before reaction with G␣ q antisera N345 (1:25 dilution) overnight in the cold. The following morning, 100 l of 20% protein A-Sepharose were added, and the samples were mixed for 3 h at room temperature and centrifuged. The recovered immunoprecipitate was washed three times with washing buffer and then suspended in 40 l of wash buffer plus 0.02% NaN 3 . Immediately before gel electrophoresis, SDS samples were prepared with low mercaptan (0.15% ␤-mercaptoethanol) 3ϫ sample buffer. Mini-gels (10.5%) were loaded with one-third total sample volume, electrophoresed, and transblotted to polyvinylidene difluoride membranes. The membranes were dried, sprayed with EN 3 HANCE, and exposed for 3 wk at Ϫ70°C on Reflection film (NEN). Palmitate labeling was evaluated through densitometric scanning of the radiogram and is expressed in arbitrary units. min; dissociation after 30-min incubation: 1-45 min), the binding reaction was terminated by the removal of cell aliquots that were immediately added to 10 ml of ice-cold HEPES buffer, followed by rapid filtration through Whatman GF/C glass fiber filters under reduced pressure. The filters were then washed twice with 10 ml of ice-cold buffer and counted. The entire filtration was complete in Ͻ15 s. Nonspecific binding was determined in the presence of 1 M I-BOP and was generally Ͻ15% of the total binding. In experiments with U-46619 or epinephrine pretreatment, cells were incubated with U-46619 (1.43 M [ 
IP
Phosphorylation of TP Receptors
The method of Carlson et al. (4) was employed. Briefly, platelets (2.5 ϫ 10 9 platelets/ml) were labeled with 0.8 mCi/ml H 3 [ 32 P]O 4 for 90 min at 30°C, washed by dilution with HEPES citrate buffer, spun, and resuspended in HEPES Tyrode buffer to 1.8 ϫ 10 9 platelets/ml. Phosphorylation reactions were conducted at room temperature with 660 l of labeled cells to which were added (at time 0) buffer, U-46619 (1.43 M), epinephrine (1 M), or epinephrine plus U-46619. To inhibit TXA 2 formation, indomethacin (5 M) was added to some samples 3 min before the beginning of the reaction. After 1 and 5 min, 300-l samples were removed, 30 l of 0.1 M EDTA were added to each sample, and the samples were spun at 2,000 rpm for 5 min. Supernatants were removed, 90 l of stopping buffer plus inhibitors (50 mM NaPO 4 , pH 8.0, 0.5% SDS, 2 mM EDTA, 1 mM DTT, 5 mM NaF, 10 mM Na 4 P 2 O 7 , 2 mM Na 3 VO 4 , 1% aprotinin, 0.5 g/ml leupeptin, and 1 mM phenylmethylsulfonyl fluoride) were added to the pellets, and the pellets were vortexed until dissolved and then heated to 90°C for 3 min. To 90 l of sample, 30 l of 4ϫ RIPA plus inhibitors were added, and the mixture was allowed to cool on ice for 30 min. Preimmune sera (1:50) was added, allowed to react for 1 h at 4°C, cleared with 20 l of protein A-Sepharose for 2 h at 4°C, and centrifuged. Sample supernatant (100 l) was removed, and TP receptor antisera N432 (1:10 dilution) was added before overnight incubation at 4°C. Protein A-Sepharose (100 l) was used to capture the immunoprecipitate, and the material was collected by centrifugation. Immunoprecipitates were washed twice, resuspended in 40 l of buffer plus 20 l of 3ϫ SDS sample buffer, and boiled for 4 min. Samples were run on 12% mini-gels, transblotted, and exposed to X-OMAT film at Ϫ70°C for 3-7 days. Phosphorylation was evaluated by densitometry and is expressed in arbitrary units.
Miscellaneous
The protein concentration was determined by dye binding using the Coomassie blue dye reagent (Bio-Rad, Hercules, CA) with ovalbumin as the standard.
Calculations
Analysis of the binding association and dissociation parameters under nonequilibrium conditions was done with the use of the computer program KINETIC (BioSoft). Statistical analysis was performed with the program Statworks using the Student's t-test. Data are expressed as means Ϯ SE unless otherwise specified.
RESULTS
Biochemical Studies
To define the mechanism of the corrective effect of epinephrine on TXA 2 Ϫ platelets, several G proteinrelated parameters were evaluated.
TP receptor-stimulated GTPase activity. Basal GTPase activities of TXA 2 Ϫ and TXA 2 ϩ platelet membranes were not significantly different from each other
The addition of U-46619 to TXA 2 ϩ membranes significantly increased GTPase activity (6.9
whole cells ϩ buffer, top).
TXA 2 ϩ membranes prepared from platelets exposed to epinephrine before membrane preparation demonstrated a nonsignificant decrease in GTPase activity (1.8 Ϯ 2.4 pmol ⅐ min Ϫ ⅐ mg Ϫ1 ), while the GTPase activity of TXA 2 Ϫ membranes similarly prepared decreased significantly (4.9 Ϯ 2.0 pmol ⅐ min Ϫ ⅐ mg Ϫ1 ) ( Fig. 1 , whole cells ϩ Epi, middle). Subsequent addition of U-46619 to these membranes significantly elevated the GTPase activity of TXA 2 ϩ (9.8 Ϯ 1.8 pmol ⅐ min Ϫ ⅐ mg Ϫ1 ) and TXA 2 Ϫ membranes (6.1 Ϯ 1.6 pmol ⅐ min Ϫ ⅐ mg Ϫ1 ) ( Fig. 1 , whole cells ϩ Epi, bottom). The increase in GTPase activity stimulated by U-46619 in TXA 2 Ϫ membranes obtained from platelets exposed to epinephrine before membrane preparation was approximately equal to that of buffer-exposed TXA 2 ϩ membranes ( Fig. 1) .
In contrast to these results, the addition of epinephrine directly to TXA 2 ϩ or TXA 2 Ϫ membranes resulted in a slight increase, rather than a decrease, in GTPase activity, and the addition of U-46619 to these membranes did not result in an additional increase in GTPase activity in either type of dog platelet (data not shown).
TP receptor-stimulated GTP␥S binding. To further evaluate the effect of TP receptor agonist binding on G protein activation, we studied GTP␥S binding to platelet membranes in the absence and presence of the TXA 2 analog I-BOP (Fig. 2) . I-BOP increased mean [ 35 S]GTP␥S binding to TXA 2 ϩ membranes at 30 min (P Ͻ 0.03, n ϭ 5). I-BOP did not increase binding to TXA 2 Ϫ membranes; however, the mean basal binding of TXA 2 Ϫ compared with TXA 2 ϩ platelet membranes was significantly elevated at 30 min (P Ͻ 0.02, n ϭ 5). Exposure of TXA 2 Ϫ platelets to epinephrine before membrane preparation decreased the basal association of [ 35 S]GTP␥S with TXA 2 Ϫ membranes, and subsequent addition of I-BOP to these membranes resulted in a significant increase in mean [
35 S]GTP␥S binding at 30 min (P Ͻ 0.05, n ϭ 2), comparable to that of TXA 2 ϩ membranes exposed to I-BOP alone. The similarity of the net I-BOP-induced increase in GTP␥S binding of TXA 2 Ϫ platelets that had been preexposed to epinephrine to that of TXA 2 ϩ platelets without epinephrine preexposure is illustrated in Fig. 2C .
TP receptor-stimulated palmitate exchange. G protein ␣-subunits are palmitoylated at their NH 2 -terminal cysteines (44) , and they undergo increased palmitate exchange on receptor activation. To determine whether impaired agonist-stimulated GTPase activity in TXA 2 Ϫ platelets was attributable to a failure to activate G␣q, [ 3 H]palmitate exchange labeling of G␣q subunits of TXA 2 ϩ and TXA 2 Ϫ platelets was carried out. The results (Fig. 3) closely parallel those obtained from the study of GTP␥S binding. In TXA 2 ϩ platelets, I-BOP stimulated an increased level of palmitate exchange (P Ͻ 0.04, n ϭ 2), but in TXA 2 Ϫ platelets, no increase was observed. Exposure of TXA 2 Ϫ platelets to epinephrine before the addition of palmitate significantly decreased basal palmitate turnover compared with control cells (P Ͻ 0.05, n ϭ 3), and the addition of I-BOP to these platelets resulted in significantly increased palmitate turnover (P Ͻ 0.03, n ϭ 3). The similarity of the net increase in palmitate exchange of TXA 2 Ϫ platelets that had been preexposed to epinephrine to that of TXA 2 ϩ platelets without epinephrine preexposure is illustrated in Fig. 3C .
Effector activation subsequent to receptor agonist binding. The results of the biochemical studies reported above indicated that TP receptor-stimulated G protein activation was impaired in TXA 2 Ϫ platelets and that it was corrected by epinephrine. To evaluate the functional consequences of epinephrine exposure, we observed its effect on activation of PLC-␤ by assaying IP 3 formation in platelets with intact cyclooxygenase activity.
In TXA 2 ϩ platelets, significant IP 3 formation was observed in response to U-46619 alone and epinephrine alone, while in TXA 2 Ϫ platelets, a much lower response to both U-46619 and epinephrine was observed (Fig. 4) . The critical observation was the significant difference between the U-46619-stimulated responses of TXA 2 ϩ vs. TXA 2 Ϫ platelets. When U-46619 was added to platelets that had been preexposed to epinephrine, IP 3 formation was significantly increased in both TXA 2 ϩ and TXA 2 Ϫ platelets (Fig. 4) , and the results were not statistically different. IP 3 formation in response to U-46619 was increased approximately threefold in TXA 2 Ϫ platelets that had been preexposed to epinephrine.
TP Receptor Kinetic Agonist Binding
To further elucidate the mechanism responsible for TXA 2 (Fig. 5A) . The rate constants for the fast and slow components of binding were determined from linear regression of the secondary plots of the observed rate constant (k obs ) vs. agonist concentration (Fig. 5B) and were analyzed according to the mass 3 H]palmitate exchange in TXA 2 ϩ platelets not exposed to Epi and TXA 2 Ϫ platelets with and without exposure to Epi. E, Platelets exposed to buffer; F, platelets exposed to I-BOP; ᮀ, platelets pretreated with Epi; s, platelets pretreated with Epi followed by I-BOP. The data presented were obtained in 1 study representative of 2-3 studies performed. 35 S]GTP to platelet membranes (ϳ56 g membrane protein/sample) was determined at room temperature over a 75-min time course in TXA 2 ϩ (A) and TXA 2 Ϫ (B) platelets. C: net I-BOP-stimulated increase in specific binding to TXA 2 ϩ membranes prepared from platelets not exposed to Epi [TXA 2 ϩ(ϪEpi)] and to TXA 2 Ϫ membranes prepared with [TXA 2 Ϫ(ϩEpi)] and without exposure of intact platelets to Epi [TXA 2 Ϫ(ϪEpi)]. E, Platelets exposed to buffer; F, platelets exposed to I-BOP; ᮀ, platelets pretreated with Epi; s, platelets pretreated with Epi followed by I-BOP. The data presented were obtained in 1 study representative of 2-5 studies performed. 0.91 nM) than the high-affinity equilibrium K d values (0.22 and 0.21 nM) that we previously observed (18) .
Human platelet association parameters resulted in a K d1 of 0.29 nM for the fast component of binding and a K d2 of 8.94 nM for the slow component of binding, values that were not significantly different from those derived from prior equilibrium binding studies (0.25 and 6 nM, respectively) (18) . In human platelets the amplitude of the fast component of binding was ϳ50% for agonist concentrations Ͻ4 nM, but subsequently it decreased with increasing substrate concentration as the K d for the numerous low-affinity receptors was approached (18) .
Because the kinetically calculated K d1 values for both types of dog platelet were higher than expected from studies of equilibrium binding, and because comparison of the graphically determined kinetic constants (Fig. 5B) ]BOP dissociation rates at equilibrium (30 min at room temperature) were measured from the same ligand reaction samples used in the association studies. Biphasic kinetic patterns were observed in all three platelet types, and the rate constants were independent of agonist concentration (Fig. 5C ). More than 95% of [ 125 I]BOP-specific binding dissociated by 150 min, indicating that virtually all of the binding was reversible.
TXA 2 ϩ platelets (n ϭ 4) exhibited a rapid dissociation of 34% of the total binding with a half-time of 3.7 min (k Ϫ1 ϭ 0.185 min ). Analysis of paired association/dissociation parameters. To further evaluate TP receptor kinetic binding parameters, we performed multiple studies with agonist concentrations of 1-2 nM (to allow comparison of dog and human platelet results with minimal interference from the abundant human low-affinity receptors), and we calculated association constants (k a ) using the relationship
, where [L] is the ligand concentration. Dissociation parameters were determined concurrently. An important result of the analysis of these data was recognition of the fact that the association/dissociation relationships expected from mass action kinetics were not observed. Instead, we observed a proportional relationship between rapidly associating and slowly dissociating TP receptors of human and both dog platelet types (Fig. 6) . TXA 2 Ϫ platelets demonstrated significantly less fast association binding (R e1 ) and slow bound ligand dissociation (R 02 ), but total binding was not significantly different from that of TXA 2 ϩ or human platelets (Fig. 6) .
The bimolecular rate constants were all less than that expected for a simple diffusion-controlled reaction and were comparable to those seen for other platelet GPCRs (32) . The fast association rate constants (k 1 ) for TXA 2 ϩ and human platelets were very similar, while the TXA 2 Ϫ platelet k 1 was significantly greater (Table  1) . These data are similar to those previously reported for kinetic [ 125 I]BOP binding to intact platelets, although a direct comparison is not possible because the data were analyzed as one site rather than two (9 After prior U-46619 incubation of TXA 2 ϩ platelets, significant changes were noted in several I-BOP binding parameters (Table 1 ). The fast rate constant (k 1 ) increased and the proportion bound (R e1 ) decreased, while the slow constant (k 2 ) decreased and the proportion bound (R e2 ) increased (Table 1 ). The amplitude of fast dissociation (R 01 ) increased, and that of slow dissociation (R 02 ) decreased significantly. Total binding (R e1 ϩ R e2 ) decreased 56 fmol/mg. Human platelet parameters, after exposure to U-46619, were similar to those observed with TXA 2 ϩ platelets (Table 1) .
In TXA 2 Ϫ platelets, U-46619 exposure resulted in a reduction in total binding of 103.1 fmol/mg and changes in association parameters that were similar to those seen in TXA 2 ϩ and human platelets, with two notable exceptions. In TXA 2 Ϫ platelets, R e2 and R 01 decreased, whereas these parameters increased in TXA 2 ϩ and human platelets.
Prior exposure of TXA 2 ϩ and human platelets to 1 M epinephrine resulted in no significant changes in association or dissociation parameters. In contrast, TXA 2 Ϫ platelets exposed to epinephrine showed significant increases in both association (R e1 ) and dissociation (R 02 ), together with significant changes in their rate constants. Total binding increased ϳ34%. The greatest parameter change observed was in the dissociation profile. This was analyzed as a statistically superior single form of dissociation (Table 1 ). These binding of I-BOP were eliminated in the presence of oxymetazoline (data not shown).
Finally, we investigated whether the effects of prior incubation with U-46619 on [
125 I]BOP binding could be reversed by subsequent exposure to epinephrine. Agonist binding rates, elevated after U-46619 exposure, were significantly decreased by epinephrine treatment to rates comparable to those observed in TXA 2 Ϫ, TXA 2 ϩ, and human platelets subsequent to epinephrine alone or to control TXA 2 ϩ and human platelets (Table 1) . Total agonist binding (R e1 ϩ R e2 ) increased in all three platelet types with statistically significant increases in R e1 in TXA 2 Ϫ, TXA 2 ϩ, and human platelets compared with the U-46619 values. The dissociation profiles similarly demonstrated significant increases in R 02 (82.2-117.3 fmol/mg) in each platelet type. After epinephrine treatment of U-46619-desensitized platelets, R e1 did not increase to control or epinephrine-treated values, suggesting that U-46619 pretreatment had permanently altered total binding capability. However, the dissociation distributions (R 01 : R 02 ) seen in U-46619-pretreated platelets were significantly shifted after epinephrine treatment to values comparable to those seen in functional TXA 2 ϩ and human controls. Moreover, total binding increased after epinephrine treatment comparable to the total increase observed after epinephrine treatment of control platelets.
Evidence that the changes in TP receptor binding distributions are related to functional consequences was obtained from studies of platelet [
14 C]5-HT secretion. TXA 2 Ϫ platelets, which demonstrated a minimal secretory response to agonist alone, secreted strongly after exposure to epinephrine followed by I-BOP. TXA 2 ϩ and human platelet secretion, eliminated by U-46619 desensitization, was restored after epinephrine exposure (data not shown).
TP Receptor Phosphorylation
Because our kinetic binding studies revealed that homologously desensitized TP receptors of TXA 2 ϩ and human platelets had impaired agonist binding similar to that observed in TXA 2 Ϫ platelets, and previous studies indicated that TP receptors were phosphorylated after desensitization (14, 23, 35) , we searched for evidence that TXA 2 Ϫ platelet TP receptors might be constitutively phosphorylated. Platelet proteins and nucleotide pools were labeled to equilibrium with H 3 [ 32 P]O 4 , and the platelets were exposed to U-46619 alone, epinephrine alone, epinephrine in the presence of indomethacin, or epinephrine plus U-46619.
Basal TP receptor phosphorylation and effect of epinephrine. Basal phosphorylation of TP receptor protein in TXA 2 Ϫ platelets was significantly higher (160%) than that observed for TXA 2 ϩ platelets (Fig. 7) . Exposure to epinephrine alone increased phosphorylation of TXA 2 ϩ platelet TP receptor protein, but this increase was indomethacin sensitive, indicating that the increase was attributable to TXA 2 . Epinephrine decreased TXA 2 Ϫ platelet TP receptor phosphorylation to a level comparable to the basal state of TXA 2 ϩ platelets, and this change was not affected by indomethacin (Fig. 7) .
Agonist-stimulated TP receptor phosphorylation. The elevated basal level of TXA 2 Ϫ platelet TP receptor phosphorylation did not increase further on exposure to U-46619 alone; however, exposure of TXA 2 ϩ and TXA 2 Ϫ platelets to epinephrine before U-46619 treatment resulted in a significant increase in TP receptor phosphorylation of both types of platelets (Fig. 7) . The increase in phosphorylation of TXA 2 Ϫ platelets over the basal level observed after exposure to epinephrine was nearly equal to that of TXA 2 ϩ platelets after exposure to U-46619 alone. TP receptor-linked G␣ q and G␣ 13 , which are phosphorylated on agonist stimulation (25, 29, 33, 43) , were quantitatively similar in TXA 2 Ϫ and TXA 2 ϩ platelets, and they migrated at lower molecular weights than TP receptors on the gels we utilized (data not shown).
DISCUSSION
The current study yielded additional evidence of impaired receptor-G q coupling in TXA 2 Ϫ platelets (e.g., diminished GTPase stimulation by TP receptor agonists and elevated basal levels of GTP␥S binding and palmitate turnover, with the latter attributable to G␣ q ). On activation, G protein ␣-subunits (G␣) exchange GDP for GTP, separate from ␤␥-subunits (G␤␥), and some G␣ undergo increased palmitate turnover (44) . They subsequently hydrolyze GTP to GDP by the intrinsic GTPase activity of G␣. G␣ q in TXA 2 Ϫ platelets appears to be cycling at an increased rate without being effectively linked to TP receptors. These results could be due to mutant G␣ q or mutant TP receptors, such as the ␤-adrenergic mutants previously described (39, 46) . However, G␣ q is not mutated (19) ; recent studies in our laboratory indicated that the TP receptor is not mutated (unpublished observation); and PLC-␤ activation in the absence of TP receptor agonists (expected from a constitutively activated receptor) is not present in TXA 2 Ϫ platelets (18) . In contrast to the impaired signal transduction via G␣ q , TXA 2 Ϫ platelet signaling via G␣ 13 is intact since G␣ 13 is not deficient, and shape change is normal (21, 22) .
An important observation made in the biochemical studies of dog platelets is that the basal level of GTPase activity, which was higher than that of human platelets, was reduced in both types of dog platelets following the addition of epinephrine, but the reduction seen in TXA 2 Ϫ platelets was approximately three times greater than that in TXA 2 ϩ platelets. This reduction in basal GTPase activity was followed by an agonist-stimulated rise in activity that was comparable to that in TXA 2 ϩ platelets. Thus we observed increased agonist-receptor-coupled GTPase stimulation, after epinephrine exposure of TXA 2 Ϫ platelets, that was indicative of G␣ q heterotrimer coupling. Subsequent studies of IP 3 formation demonstrated restoration of second messenger formation. When TXA 2 Ϫ platelets were pretreated with epinephrine, the agonist-stimulated IP 3 rise was threefold higher than that observed with epinephrine alone, indicating significantly greater PLC-␤ stimulation. That degree of stimulation was more likely the result of G␣ q stimulation of PLC-␤ 3 than G␤␥ stimulation of PLC-␤ 2 (40) . Thus these observations strongly suggest that epinephrine restored productive TP receptor-G q interaction in TXA 2 Ϫ platelets.
Because G protein activation is dependent on heterotrimer association with receptors (7), and agonist binding to GPCRs is influenced by receptor-G protein association (8, 32, 37, 46) , we studied the kinetic binding characteristics of untreated and homologously desensitized TXA 2 Ϫ and TXA 2 ϩ platelet TP receptors in the absence and presence of epinephrine. As a control, we studied intact human platelets. These studies yielded data that closely paralleled those obtained in prior studies of agonist binding to ␣ 2 -AR (31, 32) .
Three basal-state TP receptor binding parameters distinguished biochemically unresponsive TXA 2 Ϫ platelets from TXA 2 ϩ or human platelets. First, the elevated fast association rate (k 1 ) correlated with a reduced proportion of bound ligand (R e1 ) and an elevated proportion of ligand bound by slow association (R e2 ). Second, the proportion of ligand undergoing fast dissociation (R 01 ) was increased, and that involved with slow dissociation (R 02 ) was decreased. Third, TXA 2 Ϫ platelet TP receptor binding parameters were comparable to TXA 2 ϩ and human platelet parameters when TXA 2 Ϫ platelets were exposed to epinephrine, and secretion followed the addition of agonist. After homologous desensitization of TXA 2 ϩ and human platelets, fast association rates increased significantly toward those seen with simple diffusion-controlled binding. The similarity of the association rate of TXA 2 Ϫ platelets to that of desensitized platelets, previously shown to manifest receptor-G protein uncoupling (30) , was further evidence that a similar state existed in TXA 2 Ϫ platelets. The altered binding parameters and impaired function of desensitized platelets were restored by epinephrine. Thus fast-affinity TP receptor binding parameters correlated with biochemical efficacy.
Although epinephrine treatment of U-46619-desensitized platelets reversed the parameter shifts and restored biochemical responsiveness, the increased fast component of association that resulted was not equal to the sum of the loss with desensitization plus the gain from epinephrine exposure. Rather, it was similar to the increase observed with exposure to epinephrine alone. This suggested that only some of the TP receptors were restored to fast association status after epinephrine exposure or that they were derived from "spare" receptors (10) . The apparently nonrecoverable decrease in the total binding capability (R e1 ϩ R e2 ) following homologous desensitization was not due to internalization, since only ϳ1% residual [
3 H]U-46619 was detected, and internalization of TP occurs only after hours of agonist exposure (10, 30, 36, 45) .
TP receptors are phosphorylated in the absence of agonists, and agonist binding to TP receptors stimulates time-dependent and concentration-dependent increased phosphorylation (13, 14, 35) . Agonist-induced receptor phosphorylation plays an important role in TP receptor desensitization, but the influence of basal phosphorylation on receptor binding has not been evaluated. The proximal cause of impaired G q -TP receptor interaction in TXA 2 Ϫ platelets appears to be an elevated state of basal TP receptor phosphorylation. Because epinephrine resulted in a change in TP receptor binding parameters in both TXA 2 Ϫ and homologously desensitized TXA 2 ϩ and human platelets, and because it decreased the elevated phosphorylation and the elevated GTP␥S binding and palmitate cycling of TXA 2 Ϫ TP receptors, our studies suggest that basal TP receptor phosphorylation is a regulatory mechanism for TP receptor agonist binding. Epinephrine might influence TP receptor efficacy via G␤␥ liberated from ␣ 2 -AR (38) , but the mechanism is unknown.
Agonist binding to GPCRs has been characterized by cyclic agonist-receptor-G protein ternary complex models (12, 32, 39, 42) . The allosteric ternary complex model (28, 39) of agonist binding to receptors includes spontaneous isomerization (isomerization constant, J) between a resting (constrained) state, R, and an activated (relaxed) state, R*, that favors agonist binding and permits G protein interaction. Agonists may bind preferentially to the R* receptor conformation, or to other intermediate conformations (12, 27) , resulting in an increased proportion of receptors in an activated state and stabilization of the agonist-bound receptor-G protein complex (12) . The increased basal phosphorylation that we observed in TXA 2 Ϫ platelets could result in a shift of receptor equilibrium toward the R configuration by impairing receptor conformational change. Conversely, the reduction in phosphorylation observed after epinephrine exposure could shift the equilibrium toward R*. Other investigators have hypothesized that high-and low-affinity TP receptors might be the result of different levels of phosphorylation (35) .
Thus phosphorylation may control the binding state of normal TP receptors by influencing the J constant of receptor isomerization. Epinephrine may potentiate TP receptor-mediated activation of normal as well as TXA 2 Ϫ platelets by reducing the basal state of receptor phosphorylation. The expected result would be an increase in fast-association ligand binding and G protein coupling that would be expressed as increased agonist potency. The data available are not sufficient to confirm this speculation, but the strong parallels between the kinetic TP receptor binding characteristics of desensitized TXA 2 ϩ and human platelets and those of TXA 2 Ϫ platelets, plus the effects of epinephrine on TP receptor binding and function, provide support for this hypothesis. Basal receptor phosphorylation is a potentially important control mechanism for GPCRs that merits further study.
